Hemab Therapeutics (COAG) vs Omeros (OMER)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Hemab Therapeutics is the larger company by market cap ($1.44 billion vs $1.38 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | COAG | OMER |
|---|---|---|
| Share price | $30.84 | $19.03 |
| Market cap | $1.44B | $1.38B |
| 1-day change | +7.44% | +1.49% |
| YTD return | — | +9.14% |
| 1-year return | — | +322.30% |
| 5-year return | — | +142.56% |
| P/E ratio (TTM) | — | 15.60 |
| Forward P/E | — | 15.47 |
| EPS (TTM) | $-4.33 | $1.22 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $55.42 | $21.24 |
| 52-week low | $23.00 | $4.06 |
| Distance from 52-week high | -44.36% | -10.40% |
| Analyst consensus | none | none |
| Avg. price target upside | +98.48% | +44.51% |
| Average volume | 453.97K | 1.74M |
| Shares outstanding | 46.71M | 72.39M |
| Employees | 59 | 175 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Hemab Therapeutics
COAG stock →Hemab Therapeutics Holdings, Inc. operates as a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience in United States of America and Denmark.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 59 employees
About Omeros
OMER stock →Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome.
Health Care · Biotechnology: Pharmaceutical Preparations · 175 employees
COAG vs OMER FAQ
Which is bigger, Hemab Therapeutics or Omeros?
Hemab Therapeutics (COAG) is larger, with a market capitalization of $1.44B compared with $1.38B for Omeros (OMER).
Are Hemab Therapeutics and Omeros in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Hemab Therapeutics and Biotechnology: Pharmaceutical Preparations for Omeros.